Author + information
- Received April 2, 2019
- Revision received July 9, 2019
- Accepted July 10, 2019
- Published online December 23, 2019.
- Anki Knutsson, PhDa,
- Harry Björkbacka, PhDb,
- Pontus Dunér, PhDb,
- Gunnar Engström, MD, PhDb,
- Christoph J. Binder, MD, PhDc,
- Anna Hultgårdh Nilsson, PhDa and
- Jan Nilsson, MD, PhDb,∗ ()
- aDepartment of Experimental Medical Science, Lund University, Lund, Sweden
- bDepartment of Clinical Sciences Malmö, Lund University, Lund, Sweden
- cDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
- ↵∗Address for correspondence:
Dr. Jan Nilsson, Department of Clinical Sciences, Jan Waldenströms gata 35, 20502 Malmö, Sweden.
• There is strong experimental evidence that IL-5 has a protective role in atherosclerosis but the clinical importance of this remains poorly studied.
• In a prospective study involving 696 subjects with a follow-up of close to 17 years we show that baseline plasma levels of IL-5 do not predict risk for coronary events and stroke.
• However, subjects with high levels of IL-5 were less likely to have a carotid plaque at the baseline investigation.
• Experimental studies using a shear stress-modifying cast to the carotid artery of Apoe−/− mice deficient for IL-5 showed that lack of IL-5 was associated with increased plaque formation at sites of oscillatory blood flow.
• The findings are in line with previous experimental observations of an atheroprotective role of IL-5 but do not support the use of IL-5 measurement in cardiovascular risk prediction.
Experimental studies have suggested an atheroprotective role of interleukin (IL)-5 through the stimulation of natural immunoglobulin M antibody expression. In the present study we show that there are no associations between baseline levels of IL-5 and risk for development of coronary events or stroke during a 15.7 ± 6.3 years follow-up of 696 subjects randomly sampled from the Malmö Diet and Cancer study. However, presence of a plaque at the carotid bifurcation was associated with lower IL-5 and IL-5 deficiency resulted in increased plaque development at sites of oscillatory blood flow in Apoe−/− mice suggesting a protective role for IL-5 in plaque development.
This study was supported by grants from the Swedish Medical Research Council, the Swedish Heart-Lung foundation, Swedish Foundation for Strategic Research, and the European Union's Seventh Framework Program (FP7/2007-2013) under grant agreement VIA n°603131. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and US Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page.
- Received April 2, 2019.
- Revision received July 9, 2019.
- Accepted July 10, 2019.
- 2019 The Authors